Aimovig
Biological
Amgen Inc.
Total Payments
$56.7M
Transactions
396,469
Doctors
64,990
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.1M | 942 | 499 |
| 2023 | $2.8M | 4,780 | 2,316 |
| 2022 | $4.3M | 49,230 | 18,341 |
| 2021 | $9.5M | 93,570 | 29,685 |
| 2020 | $10.7M | 65,152 | 20,893 |
| 2019 | $15.1M | 121,614 | 33,183 |
| 2018 | $12.0M | 61,133 | 24,425 |
| 2017 | $105,427 | 48 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $28.7M | 2,688 | 50.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17.1M | 9,779 | 30.2% |
| Food and Beverage | $7.7M | 377,582 | 13.6% |
| Consulting Fee | $1.4M | 715 | 2.5% |
| Travel and Lodging | $1.4M | 5,634 | 2.4% |
| Grant | $299,998 | 6 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $100,569 | 53 | 0.2% |
| Education | $190.36 | 12 | 0.0% |
Payments by Type
Research
$28.7M
2,688 transactions
General
$28.0M
393,781 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 2 Episodic Migraine Prophylaxis EMP | Amgen Inc. | $3.4M | 5 |
| US Pt Satisfaction | Amgen Inc. | $2.6M | 0 |
| P1b study in children and adolescents with migraine | Amgen Inc. | $2.3M | 0 |
| Ph3 Pediatric CM Study. | Amgen Inc. | $2.1M | 0 |
| Work Productivity Study | Amgen Inc. | $2.0M | 0 |
| Ph3 Pediatric CM Study | Amgen Inc. | $1.9M | 0 |
| Medication Overuse Headache Study (MOH)_ | Amgen Inc. | $1.7M | 1 |
| Imaging the migraine brain pre-and post-erenumab: an MRI study to identify functional and structural changes that correlate with patient improvemen | Amgen Inc. | $1.3M | 0 |
| Phase P3 Pediatric Study (EM). | Amgen Inc. | $1.2M | 0 |
| Ph1 Q3M | Amgen Inc. | $1.1M | 0 |
| An Open Label Randomized Parallel Group Study in Healthy Volunteers to Assess the Relative Bioavail | Amgen Inc. | $1.1M | 0 |
| Phase P3 Pediatric Study (EM) | Amgen Inc. | $997,083 | 0 |
| Ph1 Q3M. | Amgen Inc. | $823,078 | 0 |
| A Multicenter, Open Label Study Assessing the Efficacy of erenumab on Interictal Migraine Related Burden | Amgen Inc. | $735,096 | 0 |
| Utilization of care and treatments for migraine | Amgen Inc. | $685,392 | 0 |
| Phase P3 Pediatric Study EM | Amgen Inc. | $636,205 | 0 |
| Erenumab - Comprehensive Assessment of Efficacy (EMBRACE) | Amgen Inc. | $520,906 | 0 |
| A Randomized, Double-Blinded, Single Site Study to Evaluate the Efficacy of Aimovig for Treatment of Facial Pain or Pressure Mimicking Rhinosinusitis | Amgen Inc. | $479,266 | 0 |
| Treatment of Acute Post-Traumatic Headache with Erenumab 140 mg, a Calcitonin Gene Related Peptide Receptor Monoclonal Antibody, in Military Service Members and Civilians with Mild Traumatic Brain Injury: A Randomized, Double Blind, Placebo Controlle | Amgen Inc. | $309,351 | 0 |
| A Randomized, Double Blind, Placebo-Controlled Single Center Phase 2 Pilot Study to Assess the Safety and Efficacy of Off-label Subcutaneous Administration of Erenumab-aooe in Patients with Temporomandibular Disorder | Amgen Inc. | $293,843 | 0 |
Top Doctors Receiving Payments for Aimovig
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Anaheim, CA | $28.9M | 2,681 |
| , DO | Neurology | Wesley Chapel, FL | $285,329 | 418 |
| , MD | Neurology | Cordova, TN | $272,272 | 310 |
| , M.D | Brain Injury Medicine | Houston, TX | $251,915 | 371 |
| , M.D | Neurology | Carlsbad, CA | $246,870 | 311 |
| , M.D | Family Medicine | Chicago, IL | $244,515 | 338 |
| , MD | Neurology | Amherst, NY | $239,859 | 366 |
| , M.D | Specialist | Brooklyn, NY | $239,155 | 255 |
| , M.D | Neurology | Jacksonville, FL | $224,575 | 278 |
| , M.D | Neurology | Scottsdale, AZ | $222,291 | 155 |
| , M.D, M.P.H | Neurology | Rochester, MN | $219,524 | 322 |
| Jan Brandes | — | Nashville, TN | $213,548 | 216 |
| , M.D | Neurology | Carlsbad, CA | $213,422 | 291 |
| , MD | Specialist | Greensboro, NC | $210,564 | 260 |
| , M.D | Neurology | Santa Monica, CA | $196,590 | 192 |
| , M.D | Neurology | Newport Beach, CA | $195,643 | 269 |
| , M.D | Neurology | Tampa, FL | $188,838 | 236 |
| , MD | Neurology | Richmond, VA | $187,547 | 195 |
| , MD | Neurology | Santa Moncia, CA | $185,885 | 212 |
| , MD | Internal Medicine | Chicago, IL | $178,763 | 274 |
| , MD | Behavioral Neurology & Neuropsychiatry | East Lansing, MI | $177,912 | 219 |
| , MD | Family Medicine | Rockford, IL | $174,642 | 239 |
| , MD | Neurology | Durham, NC | $173,934 | 289 |
| , M.D | Neurology | Lenexa, KS | $172,015 | 183 |
| , M.D | Neurology | Fairfield, CT | $170,276 | 254 |
Ad
Manufacturing Companies
- Amgen Inc. $56.7M
Product Information
- Type Biological
- Total Payments $56.7M
- Total Doctors 64,990
- Transactions 396,469
About Aimovig
Aimovig is a biological associated with $56.7M in payments to 64,990 healthcare providers, recorded across 396,469 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2017 to 2024. In 2024, $2.1M was paid across 942 transactions to 499 doctors.
The most common payment nature for Aimovig is "Unspecified" ($28.7M, 50.6% of total).
Aimovig is associated with 20 research studies, including "Phase 2 Episodic Migraine Prophylaxis EMP" ($3.4M).